Omeros Corporation (OMER) Q3 Net Loss $57.4M; YARTEMLEA Net Revenue Rose 26%

Omeros reported Q3 2026 net revenue of $35.9M for YARTEMLEA, a 26% increase from Q2, and a GAAP net loss of $57.4M. The loss included a $62.0M non-cash charge, while operating cash flow was $13.3M. The company is in the early commercial stage, with revenue growth and positive cash flow alongside pipeline investment.

Original reporting
Published Nov 16, 2026, 9:02 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 16, 2026, 9:06 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Omeros Corporation (OMER) Q3 Net Loss $57.4M; YARTEMLEA Net Revenue Rose 26% — source image
Decision brief

The 30-second read

$OMERNeutralMed
01

Why it matters

For trading, the key tension is improving sequential product revenue versus continued GAAP losses, with operating cash flow offering some support to the commercial-ramp thesis.

02

Market read

This is a company-specific quarterly update with concrete revenue and loss figures that can shift near-term positioning in Omeros.

03

What to watch

Traders may focus on whether operating cash flow can sustain while pipeline investment continues, but the article provides no guidance or forward milestones beyond the sequential revenue change.

Relevance 7/10Novelty 7/10Timing: after-hours/overnight following the Q3 results release

Background

The piece summarizes Omeros’ Q3 2026 performance, highlighting YARTEMLEA revenue growth and ongoing pipeline investment.

Company-level read

Ticker impact

$OMERNeutralMedium confidence
Context

Omeros reports Q3 2026 YARTEMLEA net revenue of $35.9M (+26% sequential) alongside a GAAP net loss of $57.4M.

Expected impact

Likely mixed reaction, with traders weighing revenue momentum against continued heavy losses and cash burn optics.

Evidence & confidence

The article provides both the revenue growth datapoint and the magnitude of the GAAP loss/non-cash charge, which typically drives near-term sentiment in early commercial-stage biotech/pharma.

Market effects

Reinforces the narrative that early commercial-stage specialty pharma can show sequential revenue growth while still carrying large accounting losses.

No clear regional spillover beyond US small/mid-cap biotech sentiment.

Limited, as the update is company-specific with no broader macro or cross-border catalyst described.

Counterpoint

The GAAP loss is heavily driven by a $62.0M non-cash charge, so the market may over-penalize accounting losses versus the $13.3M operating cash flow.

Key entities

  • Omeros Corporation

    Reports Q3 2026 YARTEMLEA net revenue growth and a GAAP net loss, including a large non-cash charge.

  • YARTEMLEA

    Omeros’ product whose Q3 net revenue rose 26% sequentially to $35.9M.

Related articles

$OMERMed

OMER Stock Eyes Worst Day In Nearly 18 Months With European Yartemlea Setback, Paper Losses Hitting Shares

Omeros (OMER) shares are down, heading for their worst day in 18 months. The company delayed Q4 and 2027 sales guidance, citing uncertainty. A clinical trial for OMS527 was postponed to 2027 due to delays in acquiring study animals. Despite this, retail sentiment on Stocktwits turned bullish, focusing on Yartemlea's launch and a partnership with Novo Nordisk. OMER stock is down 22% year-to-date.

$OMERMed

Omeros (OMER) Q3 2026 Earnings Call Transcript

Omeros (OMER) reported Q3 2026 earnings with YARTEMLEA generating $35.9M in net sales, up 26% from Q2. GAAP net loss was $57.4M, but non-GAAP net income was $4.7M. The company reduced convertible notes and repurchased shares. YARTEMLEA saw increased adoption and reimbursement advantages.

$OMERMed

Why is Omeros stock sliding today?

Omeros (OMER) stock fell 10.4% in after-hours trading after reporting Q3 2026 results. The company reported a GAAP net loss of $57.4 million, or $0.79 per share, due to a $62.0 million non-cash loss. Adjusted EPS of $0.06 beat estimates, and revenue exceeded expectations. A negative opinion from the European Medicines Agency on narsoplimab also weighed on sentiment.

$OMERMedAI 8/10

Omeros falls 10% despite revenue beat

Omeros (NASDAQ:OMER) reported Q3 revenue of $41.8M, beating estimates, but shares fell 10% due to a widened GAAP net loss of $57.4M. Adjusted earnings were $0.06 per share, exceeding expectations. YARTEMLEA sales grew 30% sequentially. The company held $95.3M in cash as of Q3 2026.

$OMERMed

Omeros Corporation Reports Third Quarter 2026 Financial Results

OMEROS CORP (OMER) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Omeros Corporation Reports Third Quarter 2026 Financial Results – Conference Call Today at 4:30 p.m. ET SEATTLE, WA – November 16, 2026 – Omeros Corporation (Nasdaq: OMER) today announced recent highlights and developments as well as financial results for the third q